Top-Rated StocksTop-RatedNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free ROIV Stock Alerts $10.44 -0.27 (-2.52%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$10.42▼$10.8050-Day Range$9.87▼$11.8052-Week Range$8.06▼$13.24Volume4.04 million shsAverage Volume6.99 million shsMarket Capitalization$8.41 billionP/E Ratio2.01Dividend YieldN/APrice Target$16.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Roivant Sciences alerts: Email Address Roivant Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside61.9% Upside$16.90 Price TargetShort InterestBearish5.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.06 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.36) to ($1.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.24 out of 5 starsMedical Sector307th out of 913 stocksPharmaceutical Preparations Industry118th out of 396 stocks 4.5 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRoivant Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.59% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Roivant Sciences has recently decreased by 2.03%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Roivant Sciences this week, compared to 5 articles on an average week.Search Interest14 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,058,694.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to grow in the coming year, from ($1.36) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is 2.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is 2.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 250.16.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 4.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Roivant Sciences Stock (NASDAQ:ROIV)Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Stock News HeadlinesApril 14, 2024 | markets.businessinsider.comSunrun (RUN) Gets a Buy from RBC CapitalApril 4, 2024 | msn.comRoivant's anti-inflammatory drug shows promise in mid-stage studyApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 2, 2024 | msn.comRoivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease StudyApril 2, 2024 | reuters.comRoivant's anti-inflammatory drug succeeds in mid-stage studyApril 2, 2024 | globenewswire.comRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionApril 1, 2024 | msn.comCompare with CoinDesk Market Index (CDICMI)March 26, 2024 | msn.comViking Therapeutics gains on early data for oral weight loss therapyApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 26, 2024 | msn.com'Some people have principles': Internet divided as Vivek Ramaswamy predicts NY ruling against Trump could energize key voter groupMarch 14, 2024 | fr.investing.comL'objectif de cours de Roivant Sciences relevé à 16$ par Goldman SachsMarch 13, 2024 | edition.cnn.comTravere Therapeutics, Inc.March 13, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)February 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Roivant Sciences: Undervaluation and Promising Pipeline Drive Positive OutlookFebruary 15, 2024 | finance.yahoo.comDo You Think the Management of Roivant Sciences (ROIV) Can Create Value?February 14, 2024 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call TranscriptFebruary 14, 2024 | markets.businessinsider.comHold Rating on Roivant Sciences Amidst Mixed Performance and Strategic FocusFebruary 14, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Roivant SciencesFebruary 14, 2024 | finance.yahoo.comRoivant Sciences Third Quarter 2024 Earnings: Beats ExpectationsFebruary 14, 2024 | markets.businessinsider.comBuy Rating for Roivant Sciences: Solid Sales and Promising Clinical DevelopmentsFebruary 14, 2024 | realmoney.thestreet.comRoivant Sciences price target lowered by $2 at Goldman Sachs, here's whyFebruary 14, 2024 | finance.yahoo.comQ3 2024 Roivant Sciences Ltd Earnings CallFebruary 13, 2024 | finance.yahoo.comRoivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business UpdateFebruary 12, 2024 | msn.comRoivant Sciences Q3 2024 Earnings PreviewFebruary 10, 2024 | finance.yahoo.comRoivant Sciences Ltd President & COO Eric Venker Sells 96,950 SharesFebruary 1, 2024 | marketwatch.comRoche Expected to Report Lower Sales, Profit -- Earnings PreviewJanuary 30, 2024 | finance.yahoo.comRoivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024See More Headlines Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/17/2024Next Earnings (Estimated)6/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees904Year FoundedN/APrice Target and Rating Average Stock Price Target$16.90 High Stock Price Target$23.00 Low Stock Price Target$12.00 Potential Upside/Downside+61.9%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.20 Trailing P/E Ratio2.01 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,009,030,000.00 Net Margins3,624.14% Pretax Margin3,461.24% Return on Equity-33.38% Return on Assets-26.06% Debt Debt-to-Equity Ratio0.06 Current Ratio27.79 Quick Ratio27.79 Sales & Book Value Annual Sales$61.28 million Price / Sales137.29 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book4.95Miscellaneous Outstanding Shares805,850,000Free Float768,777,000Market Cap$8.41 billion OptionableOptionable Beta1.34 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Matthew Gline (Age 40)CEO & Director Comp: $1.77MDr. Eric Venker M.D. (Age 37)Pharm.D., President & COO Comp: $1.28MDr. Mayukh Sukhatme M.D. (Age 48)President, Chief Investment Officer & Director Comp: $1.72MMr. Richard Pulik (Age 45)Chief Financial Officer Ms. Rakhi Kumar (Age 44)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Jo ChenGeneral CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 56)Head of Global Transactions & Risk Management Mr. Alex GasnerExecutive Vice President of Roivant HealthMore ExecutivesKey CompetitorsImmunoGenNASDAQ:IMGNRayzeBioNASDAQ:RYZBCrinetics PharmaceuticalsNASDAQ:CRNXBio-Rad LaboratoriesNYSE:BIOQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsEdge Wealth Management LLCSold 9,300 shares on 4/16/2024Ownership: 0.011%Vanguard Group Inc.Bought 1,473,085 shares on 3/11/2024Ownership: 0.878%Wellington Management Group LLPSold 1,202,560 shares on 3/5/2024Ownership: 1.693%Virtu Financial LLCBought 12,118 shares on 2/26/2024Ownership: 0.002%Eventide Asset Management LLCSold 546,362 shares on 2/20/2024Ownership: 0.142%View All Insider TransactionsView All Institutional Transactions ROIV Stock Analysis - Frequently Asked Questions Should I buy or sell Roivant Sciences stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks. What is Roivant Sciences' stock price target for 2024? 10 Wall Street analysts have issued 12 month price targets for Roivant Sciences' stock. Their ROIV share price targets range from $12.00 to $23.00. On average, they predict the company's stock price to reach $16.90 in the next twelve months. This suggests a possible upside of 61.9% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts. How have ROIV shares performed in 2024? Roivant Sciences' stock was trading at $11.23 on January 1st, 2024. Since then, ROIV shares have decreased by 7.0% and is now trading at $10.44. View the best growth stocks for 2024 here. When is Roivant Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our ROIV earnings forecast. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings data on Tuesday, February, 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07. The firm had revenue of $37.14 million for the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative trailing twelve-month return on equity of 33.38%. What ETFs hold Roivant Sciences' stock? ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and ProShares Ultra Nasdaq Biotechnology (BIB).iShares Biotechnology ETF (IBB). Who are Roivant Sciences' major shareholders? Roivant Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Edge Wealth Management LLC (0.01%). Insiders that own company stock include Eric Venker, Matthew Gline, Pharma Technologies Ltd Dexcel, Keith S Manchester, Svf Investments (Uk) Ltd, Rakhi Kumar, Sciences Ltd Roivant, Vivek Ramaswamy, Financial Lp Qvt, Richard Pulik and Global Investors Lp Viking. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ROIV) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.